SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tom DuBois who wrote (970)7/15/1997 3:36:00 PM
From: JOHN W.   of 6136
 
Tom, that is exactly what I thought. The way it was explained to me was that this was a commitement by Roche for global development of Agouron's pipeline with JT. No higher amt of $6M is required. The existing ties with Roche have grown (Alanex was more significant than reported). Roche intends to make AGPH a "subsidary". He/She would not tell me the terms of the deal or when to expect the announcement. So whether the amt was $6M or $60M, it goes back to Roche eventually after the "deal" is announced. Iwould guess within the next 6-12 months timeframe.

Note: In all the revenue predictions no one gives even a dollar for sales outside the U.S.

Regards, John.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News